SEC Form 4 · accession 0001209191-15-002257
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elaine Ullian
Director
Period of report
Jan 2, 2015
Accepted (ET)
Jan 6, 2015 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2015 | M | 5,000 | $34.32 | A | 10,265 | D | |
| Common Stock | Jan 2, 2015 | S | 100 | $118.91 | D | 10,165 | D | |
| Common StockF2,F3 | Jan 2, 2015 | S | 1,700 | $122.15 | D | 8,465 | D | |
| Common StockF3,F4 | Jan 2, 2015 | S | 3,100 | $122.96 | D | 5,365 | D | |
| Common Stock | Jan 2, 2015 | S | 100 | $123.57 | D | 5,265 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $34.32 | Jan 2, 2015 | M | 5,000 | D | — | May 31, 2016 | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $122.15 (range $121.53 to $122.48).
- F3Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $122.96 (range $122.54 to $123.41).
- F5Fully vested.